HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

Overview of attention for article published in BMC Cancer, July 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 8 Dimensions

Readers on

mendeley: 12 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 8 publications that cite this research output.

8

The most recent citing publications are shown below. View all 8 publications that cite this research output on Dimensions.

Effectiveness of Immunotherapy in Non-Small Cell Lung Cancer Patients with a Diagnosis of COPD: Is This a Hidden Prognosticator for Survival and a Risk Factor for Immune-Related Adverse Events?

Article in Cancers (March 2024)

Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products

Preprint in bioRxiv (February 2024)

Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancer

Article in Scientific Reports (January 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.